Skip to main
FDMT

FDMT Stock Forecast & Price Target

FDMT Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

4D Molecular Therapeutics is positioned to be a leader in the gene therapy space, with a strong focus on ophthalmology and cardiology therapies. Their gene therapy asset 4D-150 has shown potential in treating wet age-related macular edema and diabetic macular edema and is expected to reach commercial success with its convenient route of administration and promising safety profile. Despite competition from other emerging therapies, 4D has a solid plan for commercialization and a well-rounded pipeline with potential for future growth in the cystic fibrosis gene therapy market. With their recent positive clinical trial results and plans for upcoming phase II and III trials, 4D is positioned for success in the gene therapy industry.

Bears say

4D Molecular Therapeutics is a developmental biotechnology company focusing on gene therapies for multiple therapeutic areas, including ophthalmology, cardiology, and pulmonology. Despite the company's promising product candidates and delivery technology, there are several risks that may impact its success, including the need for additional financing before achieving profitability and the uncertainty of regulatory approval for gene therapy products. These risks could lead to a downward revision of the company's target price.

FDMT has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 4D Molecular Therapeutics (FDMT) Forecast

Analysts have given FDMT a Strong Buy based on their latest research and market trends.

According to 6 analysts, FDMT has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

4D Molecular Therapeutics (FDMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.